Integra lifesciences (IART) Given Average Rating of “Hold” by Brokerages

Integra lifesciences (NASDAQ:IART) has been given an average rating of “Hold” by the eighteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Eleven investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $59.42.

IART has been the subject of several recent analyst reports. BidaskClub upgraded shares of Integra lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, March 23rd. Oppenheimer set a $58.00 target price on shares of Integra lifesciences and gave the stock a “buy” rating in a research note on Thursday, March 29th. Jefferies Group restated a “buy” rating and issued a $63.00 target price on shares of Integra lifesciences in a research note on Thursday, March 1st. BTIG Research initiated coverage on shares of Integra lifesciences in a research note on Thursday, April 5th. They issued a “neutral” rating and a $56.00 target price for the company. Finally, JPMorgan Chase raised their target price on shares of Integra lifesciences from $50.00 to $55.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 11th.

In other Integra lifesciences news, major shareholder Richard E. Caruso sold 32,880 shares of the firm’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $53.68, for a total transaction of $1,764,998.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Keith Bradley sold 15,658 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $55.00, for a total transaction of $861,190.00. Following the transaction, the director now owns 37,074 shares of the company’s stock, valued at $2,039,070. The disclosure for this sale can be found here. Insiders sold a total of 80,765 shares of company stock valued at $4,376,248 in the last quarter. Insiders own 5.10% of the company’s stock.

A number of large investors have recently bought and sold shares of IART. Louisiana State Employees Retirement System increased its holdings in Integra lifesciences by 6.6% during the 4th quarter. Louisiana State Employees Retirement System now owns 27,300 shares of the life sciences company’s stock valued at $1,307,000 after acquiring an additional 1,700 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Integra lifesciences by 10.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 323,610 shares of the life sciences company’s stock valued at $15,488,000 after acquiring an additional 29,836 shares in the last quarter. Fox Run Management L.L.C. purchased a new position in Integra lifesciences during the 4th quarter valued at about $388,000. Diversified Trust Co increased its holdings in Integra lifesciences by 8.5% during the 4th quarter. Diversified Trust Co now owns 13,317 shares of the life sciences company’s stock valued at $637,000 after acquiring an additional 1,047 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management UK Ltd. increased its holdings in Integra lifesciences by 83.3% during the 4th quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 37,400 shares of the life sciences company’s stock valued at $1,789,000 after acquiring an additional 17,000 shares in the last quarter. Hedge funds and other institutional investors own 89.68% of the company’s stock.

Shares of IART stock traded up $0.69 during mid-day trading on Friday, hitting $64.78. The stock had a trading volume of 198,858 shares, compared to its average volume of 586,276. Integra lifesciences has a fifty-two week low of $63.13 and a fifty-two week high of $63.52. The stock has a market capitalization of $5.61 billion, a PE ratio of 33.39, a price-to-earnings-growth ratio of 1.92 and a beta of 0.66. The company has a debt-to-equity ratio of 1.77, a quick ratio of 1.66 and a current ratio of 2.53.

Integra lifesciences (NASDAQ:IART) last released its earnings results on Wednesday, April 25th. The life sciences company reported $0.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.09. Integra lifesciences had a net margin of 5.39% and a return on equity of 17.90%. The company had revenue of $357.10 million during the quarter, compared to analysts’ expectations of $349.15 million. During the same quarter last year, the business earned $0.39 EPS. The business’s revenue was up 38.1% on a year-over-year basis. equities analysts forecast that Integra lifesciences will post 2.41 earnings per share for the current fiscal year.

Integra lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Analyst Recommendations for Integra lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply